Articles

Qiming Venture Partners and Over 10 Portfolio Companies Named to 2024 China Healthcare Industry Investment Glory List

Qiming Venture Partners and Over 10 Portfolio Companies Named to 2024 China Healthcare Industry Investment Glory List

The list not only recognizes outstanding investment institutions, investors, and companies, but also provides directional guidance for the evolution of industry investment logic, redefines the value standards for talent, and brings positive momentum to the industrial ecosystem.

Qiming Star | CANbridge Pharma's velaglucerase alfa for injection (brand name: Gerining), a first-in-class drug for Type I and Type III Gaucher disease, approved for market launch in China

Qiming Star | CANbridge Pharma's velaglucerase alfa for injection (brand name: Gerining), a first-in-class drug for Type I and Type III Gaucher disease, approved for market launch in China

Gorenicin is not only the third rare disease treatment drug launched by CANbridge after Hymricin and Myrbetriq, but also the first self-developed product poised for commercialization.

MiniMax Releases Next-Generation Voice Model, Claiming Top Spots on Two Global Benchmarks | Yunqi Capital

MiniMax Releases Next-Generation Voice Model, Claiming Top Spots on Two Global Benchmarks | Yunqi Capital

Recently, **Yunqi Capital portfolio company MiniMax**, a leading domestic AI model startup, released its next-generation text-to-speech system **MiniMax Speech-02**, which **ranked first on both** the authoritative international benchmarking platforms Artificial Analysis Speech Arena and Hugging Face TTS Arena, comprehensively surpassing Ope